Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A drug in clinical trials has been shown to preserve insulin-producing pancreatic beta cells in nearly half of subjects newly diagnosed with type 1 diabetes. Results of the phase 2 trials are published in the journal Diabetes.
In type 1 diabetes, a malfunction in the immune system's inflammatory response kills off the beta cells that produce insulin in the pancreas.
Trials of therapies to moderate this autoimmune destruction in new-onset type 1 diabetes (T1D) have shown success, but not everyone responds, and the response duration has been limited.
The reasons why some patients respond better than others, and why earlier immune therapies have not induced lasting remissions of the disease, have not been known.
http://www.domain-b.com/technology/Health_Medicine/20130806_diabetes.html
In type 1 diabetes, a malfunction in the immune system's inflammatory response kills off the beta cells that produce insulin in the pancreas.
Trials of therapies to moderate this autoimmune destruction in new-onset type 1 diabetes (T1D) have shown success, but not everyone responds, and the response duration has been limited.
The reasons why some patients respond better than others, and why earlier immune therapies have not induced lasting remissions of the disease, have not been known.
http://www.domain-b.com/technology/Health_Medicine/20130806_diabetes.html